Literature DB >> 16282462

Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1.

Matthew J Cotter1, Anne K Zaiss, Daniel A Muruve.   

Abstract

Neutrophils are effectors of the innate immune response to adenovirus vectors. Following the systemic administration of Cy2-labeled AdLuc in mice, flow cytometry and PCR analysis of liver leukocytes revealed that 25% of recruited neutrophils interacted with adenovirus vectors. In vitro, flow cytometry of human neutrophils incubated with Cy2-labeled AdLuc also demonstrated a significant interaction with adenovirus vectors. Fluorescence and electron microscopy confirmed vector internalization by neutrophils. The AdLuc-neutrophil interaction reduced vector transduction efficiency by more than 50% in coincubation assays in epithelium-derived cells. Adenovirus vector uptake by neutrophils occurred independently of coxsackievirus adenovirus receptor (CAR) and capsid RGD motifs, since neutrophils do not express CAR and uptake of the RGD-deleted vector AdL.PB* was similar to that of AdLuc. Furthermore, both AdLuc and AdL.PB* activated neutrophils and induced similar degrees of L-selectin shedding. Neutrophil uptake of AdLuc was dependent on the presence of complement and antibodies, since the interaction between AdLuc and neutrophils was significantly reduced when they were incubated in immunoglobulin G-depleted or heat-inactivated human serum. Blocking of complement receptor 1 (CD35) but not complement receptor 3 (CD11b/CD18) significantly reduced neutrophil uptake of AdLuc. Blocking of Fc gammaRI (CD64), Fc gammaRII (CD32), and Fc gammaRIII (CD16) individually or together also reduced neutrophil uptake of AdLuc, although less than blocking of CD35 alone. Combined CR1 and Fc receptor blockade synergistically inhibited neutrophil-AdLuc interactions close to baseline. These results demonstrate opsonin-dependent adenovirus vector interactions with neutrophils and their corresponding receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282462      PMCID: PMC1287577          DOI: 10.1128/JVI.79.23.14622-14631.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration.

Authors:  F A Nunes; E E Furth; J M Wilson; S E Raper
Journal:  Hum Gene Ther       Date:  1999-10-10       Impact factor: 5.695

2.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.

Authors:  R Alemany; D T Curiel
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

3.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

4.  Role of p38 mitogen-activated protein kinase in chemokine-induced emigration and chemotaxis in vivo.

Authors:  D C Cara; J Kaur; M Forster; D M McCafferty; P Kubes
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

5.  Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10.

Authors:  Lee Anne Tibbles; Jason C L Spurrell; Gloria P Bowen; Qiang Liu; Mindy Lam; Anne K Zaiss; Stephen M Robbins; Morley D Hollenberg; Thomas J Wickham; Daniel A Muruve
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 6.  Gene therapy: trials and tribulations.

Authors:  N Somia; I M Verma
Journal:  Nat Rev Genet       Date:  2000-11       Impact factor: 53.242

7.  Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria.

Authors:  U Fagiolo; F Kricek; C Ruf; A Peserico; A Amadori; M Cancian
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

8.  Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity.

Authors:  Dmitry M Shayakhmetov; Anuj Gaggar; Shaoheng Ni; Zong-Yi Li; André Lieber
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver.

Authors:  Yang Li; Daniel A Muruve; Robert G Collins; Samuel S Lee; Paul Kubes
Journal:  Eur J Immunol       Date:  2002-12       Impact factor: 5.532

10.  Complement activation by recombinant adenoviruses.

Authors:  G Cichon; S Boeckh-Herwig; H H Schmidt; E Wehnes; T Müller; P Pring-Akerblom; R Burger
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

View more
  30 in total

1.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

2.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 3.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

Review 4.  Gene therapy works in animal models of rheumatoid arthritis...so what!

Authors:  Fons A J van de Loo; Jeroen Geurts; Wim B van den Berg
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 5.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

6.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

7.  FX and host defense evasion tactics by adenovirus.

Authors:  Andrew H Baker; Stuart A Nicklin; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

8.  GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.

Authors:  Maureen N Ajuebor; Yijun Jin; Griffin L Gremillion; Robert M Strieter; Qingling Chen; Patrick A Adegboyega
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization.

Authors:  Jason G Smith; Mariena Silvestry; Steffen Lindert; Wuyuan Lu; Glen R Nemerow; Phoebe L Stewart
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

10.  Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitis.

Authors:  Ashish V Chintakuntlawar; Xiaohong Zhou; Jaya Rajaiya; James Chodosh
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.